Patient, disease, and transplant characteristics
| Variable . | BM . | PB . | P . |
|---|---|---|---|
| No. of patients | 225 | 71 | |
| Median age, y (range) | 19 (2-66) | 36 (1-71) | < .001 |
| Age at transplantation, y | < .001 | ||
| ≤ 20 | 133 (59) | 16 (23) | |
| 21-40 | 66 (29) | 29 (41) | |
| > 40 | 26 (12) | 26 (37) | |
| Sex | .005 | ||
| Male | 109 (48) | 48 (68) | |
| Female | 116 (52) | 23 (32) | |
| Karnofsky score | .04 | ||
| < 90 | 45 (20) | 23 (32) | |
| ≥ 90 | 163 (72) | 44 (62) | |
| Not reported | 17 (8) | 4 (6) | |
| Median time from diagnosis to transplantation, mo (range) | 13 (2-318) | 11 (1-121) | .37 |
| Time from diagnosis to transplantation, mo | .42 | ||
| < 12 | 108 (48) | 38 (54) | |
| ≥ 12 | 117 (52) | 33 (46) | |
| Conditioning regimen | < .001 | ||
| TBI 200-800 cGy + Cy ± ATG ± fludarabine | 136 (61) | 32 (45) | |
| TBI ≥ 1200 + Cy ± ATG | 16 (7) | 3 (4) | |
| Busulphan or melphalan + fludarabine ± ATG | 9 (4) | 15 (21) | |
| Cy + ATG ± fludarabine | 64 (28) | 21 (30) | |
| Donor-recipient sex match | .010 | ||
| Male-male | 84 (37) | 32 (45) | |
| Male-female | 81 (36) | 13 (18) | |
| Female-male | 25 (11) | 16 (23) | |
| Female-female | 35 (16) | 10 (14) | |
| Year of transplantation | .120 | ||
| 2000-2002 | 38 (17) | 5 (7) | |
| 2003-2005 | 80 (36) | 29 (41) | |
| 2006-2008 | 107 (48) | 37 (52) | |
| GVHD prophylaxis | < .001 | ||
| Cyclosporine + methotrexate ± other | 135 (59) | 15 (21) | |
| Cyclosporine ± other | 19 (8) | 13 (18) | |
| Tacrolimus | 62 (28) | 28 (38) | |
| Mycophenylate mofetil + other | 0 | 1 (1) | |
| Tacrolimus + other | 9 (4) | 14 (20) | |
| Median follow-up of survivors, months | 35 (3-111) | 35 (3-61) |
| Variable . | BM . | PB . | P . |
|---|---|---|---|
| No. of patients | 225 | 71 | |
| Median age, y (range) | 19 (2-66) | 36 (1-71) | < .001 |
| Age at transplantation, y | < .001 | ||
| ≤ 20 | 133 (59) | 16 (23) | |
| 21-40 | 66 (29) | 29 (41) | |
| > 40 | 26 (12) | 26 (37) | |
| Sex | .005 | ||
| Male | 109 (48) | 48 (68) | |
| Female | 116 (52) | 23 (32) | |
| Karnofsky score | .04 | ||
| < 90 | 45 (20) | 23 (32) | |
| ≥ 90 | 163 (72) | 44 (62) | |
| Not reported | 17 (8) | 4 (6) | |
| Median time from diagnosis to transplantation, mo (range) | 13 (2-318) | 11 (1-121) | .37 |
| Time from diagnosis to transplantation, mo | .42 | ||
| < 12 | 108 (48) | 38 (54) | |
| ≥ 12 | 117 (52) | 33 (46) | |
| Conditioning regimen | < .001 | ||
| TBI 200-800 cGy + Cy ± ATG ± fludarabine | 136 (61) | 32 (45) | |
| TBI ≥ 1200 + Cy ± ATG | 16 (7) | 3 (4) | |
| Busulphan or melphalan + fludarabine ± ATG | 9 (4) | 15 (21) | |
| Cy + ATG ± fludarabine | 64 (28) | 21 (30) | |
| Donor-recipient sex match | .010 | ||
| Male-male | 84 (37) | 32 (45) | |
| Male-female | 81 (36) | 13 (18) | |
| Female-male | 25 (11) | 16 (23) | |
| Female-female | 35 (16) | 10 (14) | |
| Year of transplantation | .120 | ||
| 2000-2002 | 38 (17) | 5 (7) | |
| 2003-2005 | 80 (36) | 29 (41) | |
| 2006-2008 | 107 (48) | 37 (52) | |
| GVHD prophylaxis | < .001 | ||
| Cyclosporine + methotrexate ± other | 135 (59) | 15 (21) | |
| Cyclosporine ± other | 19 (8) | 13 (18) | |
| Tacrolimus | 62 (28) | 28 (38) | |
| Mycophenylate mofetil + other | 0 | 1 (1) | |
| Tacrolimus + other | 9 (4) | 14 (20) | |
| Median follow-up of survivors, months | 35 (3-111) | 35 (3-61) |
Cy indicates cyclophosphamide.